Dalbir S Sandhu

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint Treatment options for hepatocellular carcinoma
    Dalbir S Sandhu
    Miles and Shirley Fiterman Center for Digestive Diseases, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Expert Rev Gastroenterol Hepatol 2:81-92. 2008
  2. pmc Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo
    Jin Ping Lai
    Miles and Shirley Fiterman Center for Digestive Diseases, College of Medicine, Mayo Clinic and Mayo Clinic Cancer Center, 200 First Street SW, Rochester, MN 55905, USA
    J Hepatol 50:1112-21. 2009
  3. pmc Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors
    Jin Ping Lai
    Miles and Shirley Fiterman Center for Digestive Diseases, College of Medicine, Mayo Clinic and Mayo Clinic Cancer Center, Rochester, MN, USA
    Liver Int 30:1522-8. 2010
  4. pmc Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets
    Jin Ping Lai
    Center for Basic Research in Digestive Diseases, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine and Mayo Clinic Cancer Center, 200 First Street, SW, Rochester, MN 55905, USA
    Future Oncol 4:803-14. 2008
  5. pmc The tumor suppressor function of human sulfatase 1 (SULF1) in carcinogenesis
    Jin Ping Lai
    Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Gastrointest Cancer 39:149-58. 2008
  6. pmc Viral hepatitis among Somali immigrants in Minnesota: association of hepatitis C with hepatocellular carcinoma
    Abdirashid M Shire
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 87:17-24. 2012
  7. pmc Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma
    Jin Ping Lai
    Miles and Shirley Fiterman Center for Digestive Diseases, College of Medicine, Mayo Clinic and Mayo Clinic Cancer Center, Rochester, MN 55905, USA
    Hepatology 47:1211-22. 2008
  8. ncbi request reprint Diagnosis and management of cholangiocarcinoma
    Dalbir S Sandhu
    Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Curr Gastroenterol Rep 10:43-52. 2008

Collaborators

Detail Information

Publications8

  1. doi request reprint Treatment options for hepatocellular carcinoma
    Dalbir S Sandhu
    Miles and Shirley Fiterman Center for Digestive Diseases, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Expert Rev Gastroenterol Hepatol 2:81-92. 2008
    ..Recent positive results from a large Phase III study of the receptor tyrosine kinase inhibitor, sorafenib, hold great promise in the treatment of HCC...
  2. pmc Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo
    Jin Ping Lai
    Miles and Shirley Fiterman Center for Digestive Diseases, College of Medicine, Mayo Clinic and Mayo Clinic Cancer Center, 200 First Street SW, Rochester, MN 55905, USA
    J Hepatol 50:1112-21. 2009
    ..We investigated the effects of the histone deacetylase inhibitor apicidin in combination with doxorubicin in SULF1-expressing HCC cells in vitro and in SULF1-expressing xenografts in nude mice...
  3. pmc Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors
    Jin Ping Lai
    Miles and Shirley Fiterman Center for Digestive Diseases, College of Medicine, Mayo Clinic and Mayo Clinic Cancer Center, Rochester, MN, USA
    Liver Int 30:1522-8. 2010
    ..SULF2 also increases phosphorylation of the anti-apoptotic Akt kinase substrate GSK3β and SULF2 expression is associated with a decreased apoptotic index in human HCCs...
  4. pmc Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets
    Jin Ping Lai
    Center for Basic Research in Digestive Diseases, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine and Mayo Clinic Cancer Center, 200 First Street, SW, Rochester, MN 55905, USA
    Future Oncol 4:803-14. 2008
    ..Targeting SULF2 or the interaction between SULF2 and SULF1 may lead to novel therapeutics for the treatment of HCCs...
  5. pmc The tumor suppressor function of human sulfatase 1 (SULF1) in carcinogenesis
    Jin Ping Lai
    Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Gastrointest Cancer 39:149-58. 2008
    ..Since sulfated HSPGs serve as co-receptors for many growth factors and cytokines, SULF1 was predicted to modulate growth factor and cytokine signaling...
  6. pmc Viral hepatitis among Somali immigrants in Minnesota: association of hepatitis C with hepatocellular carcinoma
    Abdirashid M Shire
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 87:17-24. 2012
    ..To study the frequencies of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, and their associations with hepatocellular carcinoma (HCC) in immigrant Somalis seen at Mayo Clinic in Rochester, Minnesota...
  7. pmc Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma
    Jin Ping Lai
    Miles and Shirley Fiterman Center for Digestive Diseases, College of Medicine, Mayo Clinic and Mayo Clinic Cancer Center, Rochester, MN 55905, USA
    Hepatology 47:1211-22. 2008
    ..Conclusion: In contrast to the tumor suppressor effect of SULF1, SULF2 has an oncogenic effect in HCC mediated in part through up-regulation of FGF signaling and GPC3 expression...
  8. ncbi request reprint Diagnosis and management of cholangiocarcinoma
    Dalbir S Sandhu
    Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Curr Gastroenterol Rep 10:43-52. 2008
    ..Molecular therapies (eg, epidermal growth factor receptor, ErbB-2, and vascular endothelial growth factor receptor antagonists) and immunotherapy using diabodies are also under investigation for treatment of unresectable CC...